Renal Cell Carcinoma Pseudoprogression with Clinical Deterioration: To Hospice and Back

Saved in:
Bibliographic Details
Published inClinical genitourinary cancer Vol. 16; no. 6; pp. 485 - 488
Main Authors Elias, Roy, Kapur, Payal, Pedrosa, Ivan, Brugarolas, James
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.12.2018
Subjects
Aged
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biopsy
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - pathology
Checkpoint inhibitors
Chemoradiotherapy - methods
Clinical Deterioration
Fatal Outcome
Hospices
Humans
Hyperprogression
Immune-related adverse events
Immunotherapy
Infection
Lung Neoplasms - pathology
Lung Neoplasms - secondary
Lung Neoplasms - therapy
Male
Pleural Effusion, Malignant - diagnostic imaging
Pleural Effusion, Malignant - pathology
Pleural Effusion, Malignant - therapy
Radiosurgery
SBRT
Treatment Outcome
Tumor Burden - drug effects
Tumor Burden - radiation effects
Infection
Checkpoint inhibitors
Immune-related adverse events
Hyperprogression
Immunotherapy
SBRT
Online AccessGet full text

Cover

Author Brugarolas, James
Kapur, Payal
Pedrosa, Ivan
Elias, Roy
AuthorAffiliation 1 Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
2 Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
3 Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX
4 Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX
AuthorAffiliation_xml – name: 2 Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
– name: 1 Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
– name: 3 Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX
– name: 4 Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX
Author_xml – sequence: 1
  givenname: Roy
  surname: Elias
  fullname: Elias, Roy
  organization: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
– sequence: 2
  givenname: Payal
  surname: Kapur
  fullname: Kapur, Payal
  organization: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
– sequence: 3
  givenname: Ivan
  surname: Pedrosa
  fullname: Pedrosa, Ivan
  organization: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
– sequence: 4
  givenname: James
  surname: Brugarolas
  fullname: Brugarolas, James
  email: James.Brugarolas@utsw.edu
  organization: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30100272$$D View this record in MEDLINE/PubMed
BookMark eNp9kV1rFDEUhoNU7If-AS9kLr2Z8SQz-RIRdG2tUFCk4mXIJme2WWeTbTJb8d-bZWvRG3ORBM5z3oTznJKjmCIS8pxCR4GKV-vOTSvXMaCqA9kB5Y_ICdW9akEodlTvnKtWCtkfk9NS1gADpxKekOMeKACT7IR8_4rRTs0Cp7rZ7EJMG9t8KbjzaZvTKmMpIcXmZ5hvmsUUYnAV_4Az5pCynWvtdXOdmstUtsFhY6Nv3lv34yl5PNqp4LP784x8uzi_Xly2V58_flq8u2rdwPncKgcD4KCk1LwurwWgU9KLUVNPGXV8tHoYlVguPdMOgQlvhVauVxQsH_sz8vaQu90tN-gdxjnbyWxz2Nj8yyQbzL-VGG7MKt0ZCYozyWvAy_uAnG53WGazCcXVcdiIaVcMAyW1FoOkFWUH1OVUSsbx4RkKZm_ErM3eiNkbMSBNNVKbXvz9wYeWPwoq8OYAYB3TXcBsigsYHfqQ0c3Gp_C__N-xiJ9h
CitedBy_id crossref_primary_10_1186_s13256_022_03485_6
crossref_primary_10_1007_s42399_020_00670_w
crossref_primary_10_1136_jitc_2020_001198
crossref_primary_10_3892_mco_2023_2701
crossref_primary_10_1016_j_lungcan_2019_10_011
crossref_primary_10_1007_s00259_020_05165_3
crossref_primary_10_1158_1078_0432_CCR_18_3206
crossref_primary_10_1007_s40278_018_56057_2
Cites_doi 10.1007/s00262-018-2167-3
10.1016/S1470-2045(16)30406-5
10.1007/s00262-016-1914-6
10.1056/NEJMoa1510665
10.1200/JCO.2015.61.6870
10.1093/annonc/mdx178
10.1186/s40425-017-0287-5
10.1200/JCO.2017.74.2627
10.1038/nature13954
10.1016/j.ctrv.2017.07.002
10.1158/1078-0432.CCR-16-1741
10.1634/theoncologist.2017-0133
10.1097/COC.0b013e318209cda9
10.1186/s40425-018-0314-1
10.3322/caac.21387
10.1016/j.eururo.2017.03.037
ContentType Journal Article
Copyright 2018 Elsevier Inc.
Copyright_xml – notice: 2018 Elsevier Inc.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
5PM
DOI 10.1016/j.clgc.2018.07.015
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1938-0682
EndPage 488
ExternalDocumentID 10_1016_j_clgc_2018_07_015
30100272
S1558767318304622
Genre Journal Article
Case Reports
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: P50 CA196516
– fundername: NCI NIH HHS
  grantid: R01 CA154475
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
1P~
1~.
29B
4.4
457
4G.
53G
5GY
6J9
6PF
7-5
8P~
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQQT
AAWTL
AAXUO
ABBQC
ABDBF
ABJNI
ABLVK
ABMAC
ABMZM
ABXDB
ABYKQ
ACDAQ
ACGFS
ACRLP
ADBBV
ADEZE
ADMUD
AEBSH
AEKER
AENEX
AEVXI
AFCTW
AFKWA
AFRHN
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AJRQY
AJUYK
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
AXJTR
BKOJK
BLXMC
BNPGV
C45
CAG
COF
DU5
EBS
EFJIC
EFLBG
EJD
ESX
F5P
FDB
FEDTE
FIRID
FNPLU
FYGXN
GBLVA
HVGLF
HZ~
KOM
LCYCR
M41
MET
MO0
O-L
O9-
OAUVE
OC~
OO-
OVD
P-8
P-9
PC.
Q38
ROL
SDF
SEL
SPCBC
SSH
SSZ
T5K
TEORI
XH2
Z5R
~G-
AAXKI
AFJKZ
AKRWK
CGR
CUY
CVF
ECM
EIF
EMOBN
NPM
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c455t-8c040e487795555d960ec87d6f91d121c5fa94f86bbd29ce026da698c3810a5f3
IEDL.DBID AIKHN
ISSN 1558-7673
IngestDate Tue Sep 17 21:21:29 EDT 2024
Fri Oct 25 05:28:50 EDT 2024
Thu Sep 26 17:06:25 EDT 2024
Sat Sep 28 08:29:49 EDT 2024
Fri Feb 23 02:23:33 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords Infection
Checkpoint inhibitors
Immune-related adverse events
Hyperprogression
Immunotherapy
SBRT
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c455t-8c040e487795555d960ec87d6f91d121c5fa94f86bbd29ce026da698c3810a5f3
Notes ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
OpenAccessLink https://europepmc.org/articles/pmc7085275?pdf=render
PMID 30100272
PQID 2087996471
PQPubID 23479
PageCount 4
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7085275
proquest_miscellaneous_2087996471
crossref_primary_10_1016_j_clgc_2018_07_015
pubmed_primary_30100272
elsevier_sciencedirect_doi_10_1016_j_clgc_2018_07_015
PublicationCentury 2000
PublicationDate 2018-12-01
PublicationDateYYYYMMDD 2018-12-01
PublicationDate_xml – month: 12
  year: 2018
  text: 2018-12-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Clinical genitourinary cancer
PublicationTitleAlternate Clin Genitourin Cancer
PublicationYear 2018
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Gibney, Weiner, Atkins (bib10) 2016; 17
Siegel, Miller, Jemal (bib1) 2017; 67
Courtney, Infante, Lam (bib4) 2018; 36
Chiou, Burotto (bib7) 2015; 33
Pennock, Waterfield, Wolchok (bib5) 2012; 35
Zhu, Armstrong, Friedlander (bib11) 2018; 6
Judd, Zibelman, Handorf (bib16) 2017; 22
Jeyakumar, Kim, Bumma (bib13) 2017; 5
Tumeh, Harview, Yearley (bib12) 2014; 515
Ishihara, Pop, Takeshima, Iyengar, Hannan (bib14) 2017; 66
Champiat, Dercle, Ammari (bib8) 2017; 23
Motzer, Escudier, McDermott (bib2) 2015; 373
Queirolo, Spagnolo (bib6) 2017; 59
Saâda-Bouzid, Defaucheux, Karabajakian (bib9) 2017; 28
Fujii, Colen, Bilen (bib15) 2017
Escudier, Motzer, Sharma (bib3) 2017; 72
Wong, Thian, Kapur (bib17) 2018; 67
Escudier (10.1016/j.clgc.2018.07.015_bib3) 2017; 72
Queirolo (10.1016/j.clgc.2018.07.015_bib6) 2017; 59
Chiou (10.1016/j.clgc.2018.07.015_bib7) 2015; 33
Champiat (10.1016/j.clgc.2018.07.015_bib8) 2017; 23
Gibney (10.1016/j.clgc.2018.07.015_bib10) 2016; 17
Tumeh (10.1016/j.clgc.2018.07.015_bib12) 2014; 515
Courtney (10.1016/j.clgc.2018.07.015_bib4) 2018; 36
Judd (10.1016/j.clgc.2018.07.015_bib16) 2017; 22
Fujii (10.1016/j.clgc.2018.07.015_bib15) 2017
Motzer (10.1016/j.clgc.2018.07.015_bib2) 2015; 373
Saâda-Bouzid (10.1016/j.clgc.2018.07.015_bib9) 2017; 28
Siegel (10.1016/j.clgc.2018.07.015_bib1) 2017; 67
Zhu (10.1016/j.clgc.2018.07.015_bib11) 2018; 6
Wong (10.1016/j.clgc.2018.07.015_bib17) 2018; 67
Ishihara (10.1016/j.clgc.2018.07.015_bib14) 2017; 66
Jeyakumar (10.1016/j.clgc.2018.07.015_bib13) 2017; 5
Pennock (10.1016/j.clgc.2018.07.015_bib5) 2012; 35
References_xml – volume: 515
  start-page: 568
  year: 2014
  ident: bib12
  article-title: PD-1 blockade induces responses by inhibiting adaptive immune resistance
  publication-title: Nature
  contributor:
    fullname: Yearley
– volume: 33
  start-page: 3541
  year: 2015
  end-page: 3543
  ident: bib7
  article-title: Pseudoprogression and immune-related response in solid tumors
  publication-title: J Clin Oncol
  contributor:
    fullname: Burotto
– volume: 28
  start-page: 1605
  year: 2017
  end-page: 1611
  ident: bib9
  article-title: Hyperprogression during anti–PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
  publication-title: Ann Oncol
  contributor:
    fullname: Karabajakian
– year: 2017
  ident: bib15
  article-title: Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
  publication-title: Invest New Drugs
  contributor:
    fullname: Bilen
– volume: 373
  start-page: 1803
  year: 2015
  end-page: 1813
  ident: bib2
  article-title: Nivolumab versus everolimus in advanced renal-cell carcinoma
  publication-title: N Engl J Med
  contributor:
    fullname: McDermott
– volume: 23
  start-page: 1920
  year: 2017
  end-page: 1928
  ident: bib8
  article-title: Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti–PD-1/PD-L1
  publication-title: Clin Cancer Res
  contributor:
    fullname: Ammari
– volume: 5
  start-page: 82
  year: 2017
  ident: bib13
  article-title: Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
  publication-title: J Immunother Cancer
  contributor:
    fullname: Bumma
– volume: 36
  start-page: 867
  year: 2018
  end-page: 874
  ident: bib4
  article-title: Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell carcinoma
  publication-title: J Clin Oncol
  contributor:
    fullname: Lam
– volume: 66
  start-page: 281
  year: 2017
  end-page: 298
  ident: bib14
  article-title: Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment
  publication-title: Cancer Immunol Immunother
  contributor:
    fullname: Hannan
– volume: 67
  start-page: 1105
  year: 2018
  end-page: 1111
  ident: bib17
  article-title: Pushing the limits of immune-related response: a case of “extreme pseudoprogression
  publication-title: Cancer Immunol Immunother
  contributor:
    fullname: Kapur
– volume: 72
  start-page: 368
  year: 2017
  end-page: 376
  ident: bib3
  article-title: Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025
  publication-title: Eur Urol
  contributor:
    fullname: Sharma
– volume: 59
  start-page: 71
  year: 2017
  end-page: 78
  ident: bib6
  article-title: Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti–PD-1 drugs: a systematic review
  publication-title: Cancer Treat Rev
  contributor:
    fullname: Spagnolo
– volume: 22
  start-page: 1232
  year: 2017
  end-page: 1237
  ident: bib16
  article-title: Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors
  publication-title: Oncologist
  contributor:
    fullname: Handorf
– volume: 35
  start-page: 606
  year: 2012
  end-page: 611
  ident: bib5
  article-title: Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?
  publication-title: Am J Clin Oncol
  contributor:
    fullname: Wolchok
– volume: 6
  start-page: 4
  year: 2018
  ident: bib11
  article-title: Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
  publication-title: J Immunother Cancer
  contributor:
    fullname: Friedlander
– volume: 67
  start-page: 7
  year: 2017
  end-page: 30
  ident: bib1
  article-title: Cancer statistics, 2017
  publication-title: CA Cancer J Clin
  contributor:
    fullname: Jemal
– volume: 17
  start-page: e542
  year: 2016
  end-page: e551
  ident: bib10
  article-title: Predictive biomarkers for checkpoint inhibitor-based immunotherapy
  publication-title: Lancet Oncol
  contributor:
    fullname: Atkins
– volume: 67
  start-page: 1105
  year: 2018
  ident: 10.1016/j.clgc.2018.07.015_bib17
  article-title: Pushing the limits of immune-related response: a case of “extreme pseudoprogression
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-018-2167-3
  contributor:
    fullname: Wong
– volume: 17
  start-page: e542
  year: 2016
  ident: 10.1016/j.clgc.2018.07.015_bib10
  article-title: Predictive biomarkers for checkpoint inhibitor-based immunotherapy
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(16)30406-5
  contributor:
    fullname: Gibney
– volume: 66
  start-page: 281
  year: 2017
  ident: 10.1016/j.clgc.2018.07.015_bib14
  article-title: Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-016-1914-6
  contributor:
    fullname: Ishihara
– volume: 373
  start-page: 1803
  year: 2015
  ident: 10.1016/j.clgc.2018.07.015_bib2
  article-title: Nivolumab versus everolimus in advanced renal-cell carcinoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1510665
  contributor:
    fullname: Motzer
– volume: 33
  start-page: 3541
  year: 2015
  ident: 10.1016/j.clgc.2018.07.015_bib7
  article-title: Pseudoprogression and immune-related response in solid tumors
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2015.61.6870
  contributor:
    fullname: Chiou
– volume: 28
  start-page: 1605
  year: 2017
  ident: 10.1016/j.clgc.2018.07.015_bib9
  article-title: Hyperprogression during anti–PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdx178
  contributor:
    fullname: Saâda-Bouzid
– volume: 5
  start-page: 82
  year: 2017
  ident: 10.1016/j.clgc.2018.07.015_bib13
  article-title: Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-017-0287-5
  contributor:
    fullname: Jeyakumar
– volume: 36
  start-page: 867
  year: 2018
  ident: 10.1016/j.clgc.2018.07.015_bib4
  article-title: Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell carcinoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.74.2627
  contributor:
    fullname: Courtney
– volume: 515
  start-page: 568
  year: 2014
  ident: 10.1016/j.clgc.2018.07.015_bib12
  article-title: PD-1 blockade induces responses by inhibiting adaptive immune resistance
  publication-title: Nature
  doi: 10.1038/nature13954
  contributor:
    fullname: Tumeh
– volume: 59
  start-page: 71
  year: 2017
  ident: 10.1016/j.clgc.2018.07.015_bib6
  article-title: Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti–PD-1 drugs: a systematic review
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2017.07.002
  contributor:
    fullname: Queirolo
– volume: 23
  start-page: 1920
  year: 2017
  ident: 10.1016/j.clgc.2018.07.015_bib8
  article-title: Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti–PD-1/PD-L1
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-16-1741
  contributor:
    fullname: Champiat
– year: 2017
  ident: 10.1016/j.clgc.2018.07.015_bib15
  article-title: Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
  publication-title: Invest New Drugs
  contributor:
    fullname: Fujii
– volume: 22
  start-page: 1232
  year: 2017
  ident: 10.1016/j.clgc.2018.07.015_bib16
  article-title: Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2017-0133
  contributor:
    fullname: Judd
– volume: 35
  start-page: 606
  year: 2012
  ident: 10.1016/j.clgc.2018.07.015_bib5
  article-title: Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?
  publication-title: Am J Clin Oncol
  doi: 10.1097/COC.0b013e318209cda9
  contributor:
    fullname: Pennock
– volume: 6
  start-page: 4
  year: 2018
  ident: 10.1016/j.clgc.2018.07.015_bib11
  article-title: Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-018-0314-1
  contributor:
    fullname: Zhu
– volume: 67
  start-page: 7
  year: 2017
  ident: 10.1016/j.clgc.2018.07.015_bib1
  article-title: Cancer statistics, 2017
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21387
  contributor:
    fullname: Siegel
– volume: 72
  start-page: 368
  year: 2017
  ident: 10.1016/j.clgc.2018.07.015_bib3
  article-title: Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2017.03.037
  contributor:
    fullname: Escudier
SSID ssj0045170
Score 2.236905
SourceID pubmedcentral
proquest
crossref
pubmed
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 485
SubjectTerms Aged
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biopsy
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - pathology
Checkpoint inhibitors
Chemoradiotherapy - methods
Clinical Deterioration
Fatal Outcome
Hospices
Humans
Hyperprogression
Immune-related adverse events
Immunotherapy
Infection
Lung Neoplasms - pathology
Lung Neoplasms - secondary
Lung Neoplasms - therapy
Male
Pleural Effusion, Malignant - diagnostic imaging
Pleural Effusion, Malignant - pathology
Pleural Effusion, Malignant - therapy
Radiosurgery
SBRT
Treatment Outcome
Tumor Burden - drug effects
Tumor Burden - radiation effects
Title Renal Cell Carcinoma Pseudoprogression with Clinical Deterioration: To Hospice and Back
URI https://dx.doi.org/10.1016/j.clgc.2018.07.015
https://www.ncbi.nlm.nih.gov/pubmed/30100272
https://search.proquest.com/docview/2087996471
https://pubmed.ncbi.nlm.nih.gov/PMC7085275
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swED-xIqG9INhgK1_ypL1NoYkX1wlvUIa6VaCJgeDNcvwBhZIgaF_527lLHES3aQ_LQ6LEdnS6c8538d3vAD67IjOE4x0JbfMo5YWJcul8FBtnvS14YmoEvuOT_vA8_XEpLhdg0ObCUFhl0P2NTq-1dXjSC9zs3Y_HvV-4EuKnLGlSUoYl6uHFepOoA4v730fDk1YhpyKpa8ZR_4gGhNyZJszLTK4IyTDJagxPqo779_XpT_vz9zDKV-vS0QosB4OS7Tc0r8KCK9_B0nHYMn8PF6eO2gdugicqHFRWd5r9fHQzW9XBWQ0wB6MfsiyghE7YIUXJjMP02GNnFasLjBjHdGnZgTa3a3B-9O1sMIxCNYXIpEJMI5JJ7NA_kbnAw6Lr4kwmbd_niU1QKMLrPPVZvygsz41D58zqfp4ZwgDTwn9dh05Zle4jME6GVuZ0yj1H7saFkD4ufGZjbkVski58aXmo7hvQDNVGk90o4rgijqtYKnxTF0TLZjUneoVa_Z_jPrUyUfhN0EaHLl01e8ROmcwpxRYp-dDI6IUOVGjkivMuyDnpvXQgvO35lnJ8XeNuSzRPuRQb_0nvJryluyYWZgs604eZ20aLZlrswJvdp2QnzFu6jk4vRs8sz_dZ
link.rule.ids 230,315,783,787,888,4511,24130,27938,27939,45599,45693
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swELcQSIwXBIyPji9P2huKmpi4jnmDAiqDVtNWBG-W4w8o6xI02v-fu8RB60A8kIc8xE50ujuf7-K73xHyzeWZQRzviGsro5TlJpLC-Sg2znqbs8RUCHz9Qad3nX6_5bdzpNvUwmBaZbD9tU2vrHV40g7cbD-ORu1fsBPCUhaolFhhCXZ4AbwBCcq-cHxx2Rs0BjnlSdUzDudH-EKonanTvMz4DpEMk6zC8MTuuG_vT6_9z__TKP_Zl85XyHJwKOlxTfMqmXPFGlnshyPzz-Tmp8PxrhvDDRsHFeUfTX88uaktq-SsGpiD4g9ZGlBCx_QUs2RGQT2O6LCkVYMR46guLD3R5vc6uT4_G3Z7UeimEJmU80mEMokdxCdCcrgshC7OZMJ2vExsAkLhXsvUZ508t0waB8GZ1R2ZGcQA09wfbpD5oizcFqEMHa3M6ZR5BtyNcy58nPvMxszy2CQtctDwUD3WoBmqySZ7UMhxhRxXsVDwpRbhDZvVjOgVWPV33_vayETBmsCDDl24cvoEkzIhscQWKNmsZfRCBxg0DMVZi4gZ6b1MQLzt2ZFidF_hbgtwT5ngXz5I7z751Bv2r9TVxeBymyzhSJ0Xs0PmJ3-nbhe8m0m-F7T3GYQI97M
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Renal+Cell+Carcinoma+Pseudoprogression+with+Clinical+Deterioration%3A+To+Hospice+and+Back&rft.jtitle=Clinical+genitourinary+cancer&rft.au=Elias%2C+Roy&rft.au=Kapur%2C+Payal&rft.au=Pedrosa%2C+Ivan&rft.au=Brugarolas%2C+James&rft.date=2018-12-01&rft.eissn=1938-0682&rft.volume=16&rft.issue=6&rft.spage=485&rft_id=info:doi/10.1016%2Fj.clgc.2018.07.015&rft_id=info%3Apmid%2F30100272&rft.externalDocID=30100272
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1558-7673&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1558-7673&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1558-7673&client=summon